Is Your Biotech Startup Really Ready for VC Funding?

Most first-time biotech founders have incredible science. But when it comes to raising a Seed or Series A round, the science isn’t usually the problem.
The real challenge? Understanding how VCs actually evaluate risk and opportunity – and knowing where your company stands before you start pitching.

Download the Investment Readiness Self-Assessment

 

Here’s What Usually Happens

You’ve spent years developing breakthrough research. Your technology works. You know your science inside and out.
But when you start talking to VCs, something feels off.
You get vague responses like “Interesting work… let’s keep in touch” or “We’ll circle back in a few months.” The feedback doesn’t help you improve. And you’re left wondering what you’re missing.

Here’s the truth: VCs aren’t just evaluating your science. They’re scoring you on risk signals, team credibility, and market positioning- often in ways they don’t explicitly tell you.
What if you could see your company through their eyes and fix the weak spots before they become deal-breakers?

I’ve Been on Both Sides of This Table

My name is Fabio.
For over 15 years, I’ve worked in biotech – advising global pharma companies, guiding investors, and helping founders bring breakthrough therapies to market.
I’ve seen brilliant science fail to raise capital for completely preventable reasons. And I’ve watched founders waste months (sometimes years) pitching to the wrong investors or pitching the right investors the wrong way.
Early in my career, I experienced the “pitch and pray” approach myself. I thought great science would speak for itself. It doesn’t.
Over time, I learned that VC funding doesn’t always go to the best science-it goes to companies that are structured to match what early-stage investors are looking for. There are specific signals they want to see.
So I worked with experienced biotech VCs to reverse-engineer those signals.

My background: BSc and MSc in Biomedical Engineering from the Polytechnic University of Turin, and an Engineering Doctorate in Biopharmaceutical Process Development from Newcastle University. But more importantly, I’m passionate about helping founders translate science into clear, investable business stories.

What This Tool Does

This is a straightforward Excel-based self-assessment that shows you how VCs evaluate your company.

Here’s what you get:

• See your company as investors see it – Score yourself across 10 key criteria that VCs use to make funding decisions
• Identify your weak spots – Find the hidden issues that could quietly derail your round, even if your science is strong
• Test improvement scenarios – Run “what-if” scenarios to see exactly how changes would improve your score
• Get actionable next steps – No vague advice—just clear priorities for what to fix first
• Save months of wasted effort – Stop guessing what investors want and show up prepared
• No complicated software. No jargon. Just a simple Excel tool you can use immediately.

How This Changes Your Fundraising

Instead of walking into pitches wondering what investors are thinking, you’ll know:

• Which parts of your story are strong
• Where you’re vulnerable to investor skepticism
• Exactly what to address before your next meeting

You’ll pitch with confidence because you’ve already done the work VCs wish every founder would do.
The result? Faster fundraising. Better conversations. Less stress.

This Framework Is Investor-Validated

This assessment was reviewed and refined by leading biotech VCs across the US, EU, and China:

• Jennifer McMahon (Partner, Seroba)
• Daniela Begolo (Managing Director, EQT)
• Lucio Iannone (Managing Director, T1D Fund)
• Cheryl Zimberlin (Fund Manager, Oncode Bridge Fund)

First-time founders who’ve used this tool typically flag 3-5 high-risk issues before investors spot them.

“The framework helped me align our company narrative with how investors evaluate risk and value creation. It highlighted blind spots and materially improved the clarity of our investor presentation.”
— Nadine, CEO, Oncology Seed Stage Startup

“This is a very valuable tool.”
— Dr. Andrea P., Neurology Startup Founder

What’s Included

 

When you download the Investment Readiness Tool today:

• The complete Investment Readiness Excel Tool (Regular price £80)
• 10-category assessment framework used by top biotech investors
• Built-in scoring and improvement simulation
• Instant digital download with simple instructions
• Bonus: Curated List of Therapeutic Investors (Regular price £190)

Total Value: £270
Special Price: £20 (first 100)

My Promise to You

This tool is designed to give you real clarity, not empty promises.
If you complete the assessment and you’re still not sure what to fix next, email me within 7 days. I’ll either hop on a quick call or send you direct feedback so you have a clear roadmap forward.
You won’t be left guessing.

Ready to See Your Company Through VC Eyes?

You’ve invested years in your science. Don’t let preventable business issues stand between you and the funding you need.
The next pitch you walk into unprepared could cost you six months—or worse, a partnership that never comes back around. Early-stage funding windows are tight, and your competitors aren’t waiting.

 

Download the Investment Readiness Self-Assessment for just £20 today